New England’s Rising Biotech CEOs to Gather at April 4 Xconomy Event

Xconomy Boston — 

The life sciences industry is booming in the Boston area. Witness some of our headlines just over the past few weeks: Flagship Ventures closed a $270 million fund to invest in new biotech companies; startups RaNA and Warp Drive Bio raised significant VC rounds; pharma giant Merck led a $10 million financing of diagnostics firm Daktari. And last year, Pfizer built up its Kendall Square R&D hub and hired 400 new employees there.

So who are the entrepreneurs to watch over the next 10 years, and what can they teach the newest class of biotech executives? We’ll turn the spotlight on five of the region’s biotech CEOs at our next Boston life sciences event, “Xconomy Forum: New England’s Emerging Biotech Stars.” We have a great lineup of biotech up-and-comers, who will give presentations on their emerging companies at this event, which will be held April 4 at Biogen Idec’s campus in Kendall Square:

Chip Clark, CEO, Genocea Biosciences
Doug Fambrough, CEO, Dicerna Pharmaceuticals
Tillman Gerngross, CEO, Adimab
Joanna Horobin, CEO, Syndax Pharmaceuticals
Joseph Yanchik, CEO, Aileron Therapeutics

This afternoon conference will also feature keynote talks from George Scangos, the CEO of Biogen Idec (NASDAQ: BIIB), and Mark Levin, co-founder and partner at Third Rock Ventures.

And that’s not all. We’re also planning a panel discussion that will provide advice for securing research grants from non-profit foundations. We’ll hear from the Juvenile Diabetes Research Foundation, the Multiple Myeloma Research Foundation, and Dana Callow, managing general partner at Boston Millennia Partners a member of the board of the Leukemia & Lymphoma Society.

We hope you’ll join us for what’s sure to be a stimulating afternoon of discussions and networking on April 4. Register today for our special super-saver rate.